NYR Stock Overview
A pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular and neurological diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Nyrada Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.10 |
| 52 Week High | AU$0.17 |
| 52 Week Low | AU$0.018 |
| Beta | 1.09 |
| 11 Month Change | -28.57% |
| 3 Month Change | 63.93% |
| 1 Year Change | 376.19% |
| 33 Year Change | -56.52% |
| 5 Year Change | n/a |
| Change since IPO | -57.45% |
Recent News & Updates
Shareholder Returns
| NYR | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | -9.1% | -16.4% | 0.9% |
| 1Y | 376.2% | 32.3% | 18.4% |
Return vs Industry: NYR exceeded the Australian Pharmaceuticals industry which returned 32.2% over the past year.
Return vs Market: NYR exceeded the Australian Market which returned 18.4% over the past year.
Price Volatility
| NYR volatility | |
|---|---|
| NYR Average Weekly Movement | 26.8% |
| Pharmaceuticals Industry Average Movement | 11.9% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in AU Market | 17.5% |
| 10% least volatile stocks in AU Market | 3.2% |
Stable Share Price: NYR's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: NYR's weekly volatility has decreased from 68% to 27% over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | n/a | James Bonnar | www.nyrada.com |
Nyrada Inc., a pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular and neurological diseases. Its develops oral Proprotein Convertase Subtilisin/Kexin Type 9 inhibitor for the treatment of high blood LDL-cholesterol levels in patients poorly responsive to or unable to take statin drugs; and neuroprotectant drug to reduce long-term disability in patients with traumatic brain injury and ischaemic stroke. Nyrada Inc. was incorporated in 2017 and is based in Sydney, Australia.
Nyrada Inc. Fundamentals Summary
| NYR fundamental statistics | |
|---|---|
| Market cap | AU$20.96m |
| Earnings (TTM) | -AU$1.39m |
| Revenue (TTM) | AU$3.24m |
6.5x
P/S Ratio-15.1x
P/E RatioIs NYR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NYR income statement (TTM) | |
|---|---|
| Revenue | AU$3.24m |
| Cost of Revenue | AU$2.03m |
| Gross Profit | AU$1.21m |
| Other Expenses | AU$2.60m |
| Earnings | -AU$1.39m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0066 |
| Gross Margin | 37.37% |
| Net Profit Margin | -42.92% |
| Debt/Equity Ratio | 0% |
How did NYR perform over the long term?
See historical performance and comparison